RxDoctor Payments Data

Ana Duarte

Family · Brawley, CANPI 1023601192

Payments from drug & device makers

$3,607in general payments, 2019–2025

Across 175 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$804
  • Corcept Therapeutics$550
  • AstraZeneca$497
  • Lilly USA, LLC$293
  • GSK$220
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$183
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,607100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,607 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$32,730
FarxigaDapagliflozin Propanediol26$23,644
TrulicityDulaglutide14$12,815
RybelsusSemaglutide11$10,065
VascepaIcosapent Ethyl18$6,069
DapagliflozinDapagliflozin Propanediol11$5,595
Icosapent Ethyl22$4,627
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,634
Atorvastatin Calcium112$1,342
Rosuvastatin Calcium41$762
Metformin Hcl77$591
Levothyroxine Sodium45$556
Losartan Potassium54$527
Tamsulosin Hcl29$428
Albuterol Sulfate HfaAlbuterol Sulfate13$426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$804$42,79545 claims
AstraZenecaFarxiga$497$23,64426 claims
Lilly USA, LLCTrulicity$293$12,81514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Brawley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →